2003
Physician Knowledge of the Diagnosis and Management of Rocky Mountain Spotted Fever
O'REILLY M, PADDOCK C, ELCHOS B, GODDARD J, CHILDS J, CURRIE M. Physician Knowledge of the Diagnosis and Management of Rocky Mountain Spotted Fever. Annals Of The New York Academy Of Sciences 2003, 990: 295-301. PMID: 12860642, DOI: 10.1111/j.1749-6632.2003.tb07379.x.Peer-Reviewed Original ResearchConceptsHealth districtHigh case fatality rateRocky Mountain Spotted FeverDifferent health districtsInitiation of therapyOnset of rashDevelopment of rashOnset of symptomsPrimary care physiciansAntibiotic of choiceCase fatality ratePublic health districtsAppropriate treatment strategyFamily practice physiciansPercent of physiciansTick-borne illnessAgent of choiceEmergency medicine physiciansChildren 8 yearsNonspecific symptomsAntibiotic therapyAppropriate patientsPediatric patientsCare physiciansMedian time
1999
Serologic evidence of rickettsialpox (Rickettsia akari) infection among intravenous drug users in inner-city Baltimore, Maryland.
Comer J, Tzianabos T, Flynn C, Vlahov D, Childs J. Serologic evidence of rickettsialpox (Rickettsia akari) infection among intravenous drug users in inner-city Baltimore, Maryland. American Journal Of Tropical Medicine And Hygiene 1999, 60: 894-8. PMID: 10403316, DOI: 10.4269/ajtmh.1999.60.894.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BacterialBaltimoreCohort StudiesCross ReactionsDrinkingFemaleFluorescent Antibody Technique, IndirectHIV SeropositivityHumansIll-Housed PersonsMaleRickettsiaRickettsia InfectionsRickettsia rickettsiiRisk FactorsSeroepidemiologic StudiesSubstance Abuse, IntravenousUrban PopulationConceptsIntravenous drug usersInner-city BaltimoreDrug usersSerologic evidenceSerum samplesAcute febrile illnessR. rickettsiiR. akariHuman immunodeficiency virusSignificant risk factorsSignificant inverse associationCross-adsorption studiesPresence of antibodiesSingle serum sampleR. akari infectionFrequency of injectionsFever group rickettsiaeFebrile illnessUndetermined etiologyImmunodeficiency virusInverse associationRisk factorsGroup-specific antibodiesDrug useHigh titersHidden Mortality Attributable to Rocky Mountain Spotted Fever: Immunohistochemical Detection of Fatal, Serologically Unconfirmed Disease
Paddock C, Greer P, Ferebee T, Singleton J, McKechnie D, Treadwell T, Krebs J, Clarke M, Holman R, Olson J, Childs J, Zaki S. Hidden Mortality Attributable to Rocky Mountain Spotted Fever: Immunohistochemical Detection of Fatal, Serologically Unconfirmed Disease. The Journal Of Infectious Diseases 1999, 179: 1469-1476. PMID: 10228069, DOI: 10.1086/314776.Peer-Reviewed Original ResearchConceptsCase fatality ratioDiagnosis of RMSFIHC stainingRocky Mountain Spotted FeverLaboratory-confirmed casesAcute-phase seraTickborne infectionHidden mortalityIgM antibodiesDiagnostic titerPolymerase chain reactionIHC findingsPatient seraSerologic assaysImmunohistochemical stainingSpotted FeverImmunohistochemical detectionFatal diseasePatientsDisease controlIndirect immunofluorescenceNotifiable diseaseDiseaseUnderestimates of mortalityTissue samplesFamily Cluster of Rocky Mountain Spotted Fever
Jones T, Craig A, Paddock C, McKechnie D, Childs J, Zaki S, Schaffner W. Family Cluster of Rocky Mountain Spotted Fever. Clinical Infectious Diseases 1999, 28: 853-859. PMID: 10825050, DOI: 10.1086/515213.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BacterialCluster AnalysisFamily HealthFemaleHumansInfantMaleMiddle AgedRickettsia rickettsiiRocky Mountain Spotted Fever